Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sting agonists

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Lucid wins med ed consultancy award at Communiqué

It also sees success with a professional education programme for AbbVie

- PMLiVE

Novartis aims to lead immuno-oncology category

Firm believes its immuno-oncology pipeline will help it overtake leader Roche

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

- PMLiVE

AZ pushes immuno-oncology duo into phase III

MEDI4736 and tremelimumab achieved disease control in 48% of NSCLC patients

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links